Tel Aviv, Israel, Feb 08, 2022 – Tarsier Pharma, an advanced clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for blinding ocular diseases, has announced that its CEO and Chairperson, Dr. Daphne Haim-Langford, has presented to the European Parliament the progress Tarsier Pharma has made during the past years with EU public funding.
Tarsier Pharma has won a €2.4M grant from the EU Commission in 2019, as part of Horizon 2020 R&D Program, to support first-in-human clinical trial for TRS01, its lead product candidate in non-infectious anterior uveitis including uveitic glaucoma. Using this funding and other Company’s resources, Tarsier has conducted two successful phase I/II trials, in post-cataract inflammation and in uveitis, which demonstrated encouraging preliminary data about the safety, tolerability and efficacy of TRS01. Today Tarsier Pharma is already running its first phase-3 trial.
Daphne, CEO of Tarsier, said: “This is a great honor for me to present Tarsier’s achievements to the European Parliament. Thanks to the EU’s funding, we were able to progress significantly our clinical development work on our novel drug. I want to thank the European Commission for opening us this door. Indeed, in our efforts to bring to European patients a novel drug that may help save eyesight, we hope to contribute back for this generous investment”.
About Tarsier Pharma
Tarsier Pharma is a phase-3 pharmaceutical company, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular blinding diseases. TRS is a bio-inspired breakthrough proprietary technology platform, based on a new chemical entity with novel mechanism of action, that demonstrated safety and efficacy in a rare debilitating and blinding indication.
Lead product candidate for uveitic glaucoma
Non-infectious uveitis is an autoimmune blinding ocular inflammation, considered the third leading cause of blindness in the developed world. Tarsier’s TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma – that is considered an end-stage condition of uveitis. Once a uveitis patient has also developed glaucoma (uveitic glaucoma), the only available treatments for active inflammation, which are steroids, should be avoided due to their side effects of expediting glaucoma and vision loss. Thus, TRS01 has the potential to become the standard of care for uveitic glaucoma.